RhumbLine Advisers’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $33.7M | Sell |
63,548
-92
| -0.1% | -$42.5K | 0.03% | 530 |
|
|
2026
Q1 | $30.6M | Buy |
63,640
+1,665
| +3% | +$853K | 0.03% | 544 |
|
|
2025
Q4 | $34.8M | Sell |
61,975
-1,607
| -3% | -$912K | 0.03% | 494 |
|
|
2025
Q3 | $32.7M | Sell |
63,582
-3,889
| -6% | -$1.7M | 0.03% | 522 |
|
|
2025
Q2 | $21.2M | Sell |
67,471
-4,736
| -7% | -$1.42M | 0.02% | 680 |
|
|
2025
Q1 | $22M | Sell |
72,207
-1,113
| -2% | -$374K | 0.02% | 641 |
|
|
2024
Q4 | $24.4M | Buy |
73,320
+581
| +0.8% | +$197K | 0.02% | 598 |
|
|
2024
Q3 | $24.3M | Buy |
72,739
+2,739
| +4% | +$1.04M | 0.02% | 604 |
|
|
2024
Q2 | $28.8M | Buy |
70,000
+2,046
| +3% | +$810K | 0.03% | 500 |
|
|
2024
Q1 | $27.5M | Sell |
67,954
-2,935
| -4% | -$1.03M | 0.03% | 552 |
|
|
2023
Q4 | $21.7M | Sell |
70,889
-1,910
| -3% | -$516K | 0.02% | 634 |
|
|
2023
Q3 | $17.6M | Sell |
72,799
-2,734
| -4% | -$699K | 0.02% | 689 |
|
|
2023
Q2 | $18.1M | Sell |
75,533
-5,538
| -7% | -$1.15M | 0.02% | 699 |
|
|
2023
Q1 | $15.2M | Sell |
81,071
-548
| -0.7% | -$113K | 0.02% | 747 |
|
|
2022
Q4 | $17.3M | Buy |
81,619
+994
| +1% | +$199K | 0.02% | 660 |
|
|
2022
Q3 | $12.7M | Sell |
80,625
-660
| -0.8% | -$105K | 0.02% | 769 |
|
|
2022
Q2 | $12.2M | Buy |
81,285
+2,530
| +3% | +$366K | 0.02% | 806 |
|
|
2022
Q1 | $12.9M | Buy |
78,755
+1,827
| +2% | +$301K | 0.02% | 833 |
|
|
2021
Q4 | $16.7M | Buy |
76,928
+496
| +0.6% | +$104K | 0.02% | 707 |
|
|
2021
Q3 | $14.5M | Buy |
76,432
+1,977
| +3% | +$361K | 0.02% | 757 |
|
|
2021
Q2 | $13.2M | Sell |
74,455
-194
| -0.3% | -$33.5K | 0.02% | 842 |
|
|
2021
Q1 | $12.2M | Sell |
74,649
-2,658
| -3% | -$407K | 0.02% | 867 |
|
|
2020
Q4 | $10.8M | Buy |
77,307
+994
| +1% | +$125K | 0.01% | 870 |
|
|
2020
Q3 | $8.53M | Sell |
76,313
-7,183
| -9% | -$831K | 0.01% | 854 |
|
|
2020
Q2 | $7.77M | Sell |
83,496
-4,886
| -6% | -$416K | 0.01% | 912 |
|
|
2020
Q1 | $6.49M | Buy |
88,382
+1,476
| +2% | +$128K | 0.01% | 878 |
|
|
2019
Q4 | $7.3M | Buy |
86,906
+5,561
| +7% | +$430K | 0.01% | 1030 |
|
|
2019
Q3 | $6.84M | Buy |
81,345
+3,813
| +5% | +$288K | 0.01% | 1009 |
|
|
2019
Q2 | $5.07M | Buy |
77,532
+7,904
| +11% | +$456K | 0.01% | 1189 |
|
|
2019
Q1 | $4.11M | Buy |
69,628
+2,209
| +3% | +$132K | 0.01% | 1290 |
|
|
2018
Q4 | $3.57M | Buy |
67,419
+48,360
| +254% | +$2.65M | 0.01% | 1302 |
|
|
2018
Q3 | $1.14M | Buy |
19,059
+7,379
| +63% | +$404K | ﹤0.01% | 1949 |
|
|
2018
Q2 | $502K | Buy |
11,680
+2,049
| +21% | +$82.8K | ﹤0.01% | 2315 |
|
|
2018
Q1 | $336K | Buy |
9,631
+1,005
| +12% | +$36.7K | ﹤0.01% | 2382 |
|
|
2017
Q4 | $313K | Sell |
8,626
-1,312
| -13% | -$46K | ﹤0.01% | 2451 |
|
|
2017
Q3 | $317K | Buy |
9,938
+212
| +2% | +$6.48K | ﹤0.01% | 2532 |
|
|
2017
Q2 | $282K | Buy |
9,726
+1,140
| +13% | +$32K | ﹤0.01% | 2587 |
|
|
2017
Q1 | $256K | Buy |
8,586
+312
| +4% | +$10.1K | ﹤0.01% | 2575 |
|
|
2016
Q4 | $298K | Buy |
+8,274
| New | +$276K | ﹤0.01% | 2497 |
|
Other funds holding MEDP
WA
RhumbLine Advisers's MEDP Position: Q2 2026 in Review
RhumbLine Advisers reduced its Medpace (MEDP) stake by 0.14% in Q2 2026, selling an estimated $42.5K and leaving 63,548 shares worth $33.7M. The position accounts for 0.03% of the portfolio, ranked #530.
RhumbLine Advisers first reported a position in MEDP in Q4 2016 and has held it in 39 quarters since. The position peaked at $34.8M in Q4 2025. 695 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- RhumbLine Advisers held 63,548 shares of Medpace worth $33.7M as of Q2 2026.
- RhumbLine Advisers sold 92 Medpace shares in Q2 2026, an estimated $42.5K.
- Medpace made up 0.03% of RhumbLine Advisers's portfolio in Q2 2026, its #530 holding.
- RhumbLine Advisers first reported a position in Medpace in Q4 2016 and has held it in 39 quarters since.
- RhumbLine Advisers's Medpace position peaked at $34.8M in Q4 2025.
- 695 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.